Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.77 USD | +2.45% | +0.68% | +79.47% |
May. 14 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 1.01M | Capitalization | 264M |
---|---|---|---|---|---|
Net income 2024 * | -77M | Net income 2025 * | -101M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 262 x |
P/E ratio 2024 * |
-3.4
x | P/E ratio 2025 * |
-3.08
x | Employees | 60 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.58% |
1 day | -1.04% | ||
1 week | +5.16% | ||
Current month | -5.83% | ||
1 month | -9.61% | ||
3 months | +117.26% | ||
6 months | +92.79% | ||
Current year | +73.98% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 18-03-31 | |
Kristina Masson
FOU | Founder | 44 | 18-02-28 |
Director of Finance/CFO | 53 | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | Feb. 07 | |
Sharon Shacham
BRD | Director/Board Member | 53 | 20-09-30 |
Chief Executive Officer | 62 | 18-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.26% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 8.83 | +3.15% | 21 763 |
24-05-16 | 8.56 | -1.04% | 41,682 |
24-05-15 | 8.65 | +3.47% | 38,547 |
24-05-14 | 8.36 | -1.42% | 84,937 |
24-05-13 | 8.48 | -3.31% | 59,770 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+73.98% | 264M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.39% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- ACRV Stock